User:Mr. Ibrahem/Adalimumab

Adalimumab, sold under the brand name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. Use is generally only recommended in people who have not responded to other treatments. It is used by injection under the skin.

Common side effects include upper respiratory tract infections, pain at the site of injection, rash, and headache. Other side effects may include serious infections, cancer, anaphylaxis, reactivation of hepatitis B, multiple sclerosis, heart failure, liver failure, and aplastic anemia. Use during pregnancy is not recommended, while some feel use during breastfeeding may be safe. Adalimumab is a disease-modifying antirheumatic drug and monoclonal antibody that works by inactivating tumor necrosis factor-alpha (TNFα).

Adalimumab was approved for medical use in the United States in 2002. It is on the World Health Organization's List of Essential Medicines. It is expensive. A month supply in the United Kingdom costs the NHS about £704 as of 2018. In the United States the wholesale cost of this amount is about US$5,041. In 2014, a biosimilar came to market in India at a price of US$400 per month, and biosimilars are now available in the USA and Europe. In 2017, it was the 169th most commonly prescribed medication in the United States, with more than three million prescriptions.